Physician profile
James Lin
NPI 1821085846
$4,155.15
in general payments reported to CMS, 2019-2025
18 companies · $580 in 2025
The $580 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $558 · 2020: $822 · 2021: $413 · 2022: $577 · 2023: $574 · 2024: $631 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,682.08 | 2019-2025 | Clareon, Acrysof Iq Panoptix Uv Iol, Acrysof Iq Vivity |
| Glaukos Corporation | $1,283.11 | 2020-2025 | Idose, Istent Infinite, Idosetr |
| Carl Zeiss Meditec, INC. | $400.00 | 2020 | |
| Allergan, INC. | $178.98 | 2020-2022 | |
| Apellis Pharmaceuticals, INC. | $117.94 | 2023 | |
| New World Medical,INC. | $91.45 | 2019-2020 | |
| Sight Sciences, INC. | $66.84 | 2021-2022 | |
| Biotissue Holdings INC. | $65.49 | 2021-2025 | |
| Glaxosmithkline, LLC. | $55.73 | 2024-2025 | Trelegy Ellipta |
| Johnson & Johnson Vision Care, INC. | $34.02 | 2025 | |
| Rxsight INC | $29.75 | 2023 | Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal), Rxsight Light Delivery Device (Ldd) |
| Johnson & Johnson Surgical Vision, INC. | $27.55 | 2021-2025 | Tecnis Iol |
| Abbvie INC. | $27.33 | 2022 | |
| Horizon Therapeutics Plc | $24.30 | 2021 | |
| Rayner Intraocular Lenses Limited | $19.86 | 2025 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $18.34 | 2025 | Ryzumvi, Tyrvaya |
| Amgen INC. | $17.14 | 2024 | Tepezza |
| Sun Pharmaceutical Industries INC. | $15.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.